Tempus
Tempus, Texas Oncology Subsidiary Form Data-Focused Precision Oncology Partnership
Tempus will assist Texas Oncology subsidiary Precision Health Informatics in mining its database for precision oncology insights to inform research.
Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing
Kronos is working with Tempus to sequence patients' tumor samples in the study for MYC amplification and overexpression.
Zentalis Pharmaceuticals, Tempus Partner to Explore WEE1 Inhibitor Activity in Organoid Models
The drugmaker will use Tempus' platform to validate the ability of its WEE1 inhibitor, ZN-c3, to inhibit DNA repair pathways in genetically defined cancers.
Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance
Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.
Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
Sep 16, 2020
LabCorp's Covance Joins Tempus TIME Trial Program
May 30, 2019
Tempus Raises $200M in Series F Financing
Dec 3, 2018